Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline

Neurology

Volumn 82, Issue 23, 2014, Pages 2055-2062

  Grant, Igor ^a   Franklin Jr , Donald R ^a   Deutsch, Reena ^a   Woods, Steven P ^a   Vaida, Florin ^a   Ellis, Ronald J ^a   Letendre, Scott L ^a   Marcotte, Thomas D ^a   Atkinson, J H ^a   Collier, Ann C ^b   Marra, Christina M ^a,b   Clifford, David B ^c   Gelman, Benjamin B ^d   McArthur, Justin C ^e   Morgello, Susan ^f   Simpson, David M ^f   McCutchan, John A ^a   Abramson, Ian ^a   Gamst, Anthony ^a   Fennema Notestine, Christine ^a   Smith, Davey M ^a   Heaton, Robert K ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT; CD4 LYMPHOCYTE COUNT; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; FEMALE; FOLLOW UP; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MENTAL PERFORMANCE; PRIORITY JOURNAL; RISK FACTOR; SELF REPORT; SUBSTANCE USE;

ACTIVITIES OF DAILY LIVING; AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; TIME FACTORS; VIRAL LOAD;

EID: 84903976124     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000492     Document Type: Article

References (28)

1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-Associated neurocognitive disorders. Neurology 2007;69: 1789-1799.
2. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIVassociated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010;75: 2087-2096.
3. Sevigny JJ, Albert SM, McDermott MP, et al. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol 2007;64: 97-102.
4. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-Associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011;17: 3-16.
5. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors: Multicenter AIDS Cohort Study. Neurology 1993;43: 2245-2252.
6. Gisslen M, Price RW, Nilsson S. The definition of HIVassociated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis 2011;11: 356.
7. Torti C, Foca E, Cesana BM, Lescure FX. Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction? BMC Med 2011;9: 138.
8. Cherner M, Masliah E, Ellis RJ, et al. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 2002;59: 1563-1567.
9. Masliah E, Heaton RK, Marcotte TD, et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders: HNRC Group: The HIV Neurobehavioral Research Center. Ann Neurol 1997;42: 963-972.
10. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 2004;26: 307-319.
11. Wilkinson GS. The Wide Range Achievement Test, third edition, Wilmington, DE: Wide Range, Inc.; 1993.
12. World Health Organization. Composite International Diagnostic Interview, version 2.1, Geneva: WHO; 1997.
13. Beck AT, Steer RA, Brown GK. Beck Depression Inventory, second edition manual, San Antonio: The Psychological Corporation; 1996.
14. Chelune GJ, Heaton RK, Lehman RA. Neuropsychological and personality correlates of patients complaints of disability. In: Goldstein G, Tarter RE, eds. Advances in Clinical Neuropsychology, third edition. New York: Plenum Press; 1986: 95-126.
15. Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-Associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004;10: 317-331.
16. Valpar International Corporation. Microcomputer Evaluation and Screening Assessment (MESA) Short Form 2.
17. Tucson, AZ: Valpar International Corporation; 1986.
18. Valpar International Corporation. Computerized Assessment (COMPASS). Tucson, AZ: Valpar International Corporation; 1992.
19. Blackstone K, Moore DJ, Heaton RK, et al. Diagnosing symptomatic HIV-Associated neurocognitive disorders: self-report versus performance-based assessment of everyday functioning. J Int Neuropsychol Soc 2012;18: 79-88.
20. Woods SP, Rippeth JD, Frol AB, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol 2004;26: 759-778.
21. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65: 65-70.
22. Lentz MR, Kim WK, Lee V, et al. Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection. Neurology 2009;72: 1465-1472.
23. Ragin AB, Du H, Ochs R, et al. Structural brain alterations can be detected early in HIV infection. Neurology 2012;79: 2328-2334.
24. Sailasuta N, Ross W, Ananworanich J, et al. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS One 2012;7: e49272.
25. Spudich SS, Ances BM. Central nervous system complications of HIV infection. Top Antivir Med 2011;19: 48-57.
26. Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 2012;206: 275-282.
27. Blackstone K, Iudicello JE, Morgan EE, et al. Human immunodeficiency virus infection heightens concurrent risk of functional dependence in persons with long-Term methamphetamine use. J Addict Med 2013;7: 255-263.
28. Patton DE, Woods SP, Franklin D Jr, et al. Relationship of Medication Management Test-Revised (MMT-R) performance to neuropsychological functioning and antiretroviral adherence in adults with HIV. AIDS Behav 2012;16: 2286-2296.